| Released | Contributor | Author | Title | Pages | Price |
| 28-Nov-2009 | PriceTarget Research, Inc. |
N/A
| Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. | 65 |
$20 |
| 28-Nov-2009 | Standard & Poor's Quantitative Report |
N/A
| MAP Pharmaceuticals | 6 |
$25 |
| 27-Nov-2009 | Pechala's Reports | Lubomir Pechala | MAP PHARMACEUTICALS INC (MAPP=US) 2-weeks forecast | 1 |
$10 |
| 27-Nov-2009 | Pechala's Reports | Frantisek Pechala | MAP PHARMACEUTICALS INC (MAPP=US) 12-months forecast | 1 |
$15 |
| 26-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Industry Report for DRUGS | 18 |
$49 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Industry Value Graph: CBRX , CPEX , CYAN , DRRX , DUSA , MAPP , MRNA , RGEN -- DRUGS | 3 |
$4 |
| 26-Nov-2009 | Ford Investor Services, Inc. |
N/A
| Value Graph: MAP PHARMACEUT -- MAPP | 1 |
$4 |
| 26-Nov-2009 | Pechala's Reports | Lubomir Pechala | MAP PHARMACEUTICALS INC (MAPP=US) - REPORT FOR ACTIVE TRADERS | 4 |
$25 |
| 23-Nov-2009 | Zacks Investment Research Inc. |
N/A
| MAP PHARMACEUT (MAPP) Zacks Company Snapshot | 1 |
$10 |
| 23-Nov-2009 | ValuEngine, Inc. |
N/A
| ValuEngine Detailed Valuation Report for MAPP | 13 |
$25 |
1.48% Nasdaq 
Research Reports
